Pfizer Inc. (PFE) Holdings Cut by American International Group Inc.
American International Group Inc. cut its position in Pfizer Inc. (NYSE:PFE) by 0.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 15,371,485 shares of the biopharmaceutical company’s stock after selling 136,362 shares during the quarter. Pfizer accounts for about 1.9% of American International Group Inc.’s holdings, making the stock its 13th largest holding. American International Group Inc.’s holdings in Pfizer were worth $548,762,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Janus Henderson Group PLC increased its holdings in shares of Pfizer by 243.5% in the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after buying an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Pfizer in the 2nd quarter worth $268,389,000. Canada Pension Plan Investment Board increased its holdings in shares of Pfizer by 249.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after buying an additional 7,649,416 shares during the last quarter. Finally, Longview Partners Guernsey LTD increased its holdings in shares of Pfizer by 32.0% in the 3rd quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock worth $869,997,000 after buying an additional 5,901,100 shares during the last quarter. Institutional investors and hedge funds own 69.87% of the company’s stock.
In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The company’s revenue was up .6% on a year-over-year basis. During the same quarter last year, the firm earned $0.47 EPS. research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer announced that its board has approved a stock buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 4.04%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is 38.64%.
A number of equities analysts have recently commented on PFE shares. BMO Capital Markets reissued a “buy” rating and issued a $39.00 price target (up previously from $37.00) on shares of Pfizer in a report on Thursday, October 19th. JPMorgan Chase & Co. set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. UBS Group set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target on the stock in a report on Thursday, November 23rd. Finally, Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $39.45.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.